CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
+3.11%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.6B
AUM Growth
+$1.6B
(-37%)
Cap. Flow
-$931M
Cap. Flow
% of AUM
-58.1%
Top 10 Holdings %
Top 10 Hldgs %
75.77%
Holding
38
New
–
Increased
7
Reduced
16
Closed
8
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$73M |
| 2 |
Baxter International
BAX
|
$38.5M |
| 3 |
Humana
HUM
|
$19.8M |
| 4 |
Cigna
CI
|
$16.5M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$3.53M |
Top Sells
| 1 |
Medtronic
MDT
|
$220M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$142M |
| 3 |
PTC Therapeutics
PTCT
|
$86.6M |
| 4 |
GSK
GSK
|
$84.6M |
| 5 |
Ascendis Pharma
ASND
|
$70.1M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zimmer Biomet
ZBH
$21B
| $255M | 9.05% | 2,250,000 +645,000 | +40% | +$73M |
|
|
2
Baxter International
BAX
$12.7B
| $197M | 6.99% | 5,750,000 +1,125,000 | +24% | +$38.5M |
|
|
3
Humana
HUM
$36.5B
| $192M | 6.81% | 725,000 +75,000 | +12% | +$19.8M |
|
4
CVS Health
CVS
$92.8B
| $152M | 5.42% | 2,250,000 -750,000 | -25% | -$50.8M |
|
5
Globus Medical
GMED
$8.27B
| $91.5M | 3.25% | 1,250,000 +25,000 | +2% | +$1.83M |
|
|
6
PTC Therapeutics
PTCT
$3.92B
| $76.4M | 2.72% | 1,500,000 -1,700,000 | -53% | -$86.6M |
|
|
7
Cigna
CI
$80.3B
| $65.8M | 2.34% | 200,000 +50,000 | +33% | +$16.5M |
|
8
Viatris
VTRS
$12.3B
| $65.3M | 2.32% | 7,500,000 -7,500,000 | -50% | -$65.3M |
|
9
Pfizer
PFE
$141B
| $63.4M | 2.25% | 2,500,000 -2,500,000 | -50% | -$63.4M |
|
10
Qiagen
QGEN
$10.1B
| $56.2M | 2% | 1,400,000 -100,000 | -7% | -$4.02M |
|
|
11
Ascendis Pharma
ASND
$11.8B
| $54.6M | 1.94% | 350,000 -450,000 | -56% | -$70.1M |
|
12
Sarepta Therapeutics
SRPT
$1.78B
| $51.1M | 1.81% | 800,000 -200,000 | -20% | -$12.8M |
|
13
Brookdale Senior Living
BKD
$1.83B
| $39.1M | 1.39% | 6,250,000 -7,685,000 | -55% | -$48.1M |
|
|
14
BioMarin Pharmaceuticals
BMRN
$11.2B
| $35.3M | 1.26% | 500,000 +50,000 | +11% | +$3.53M |
|
|
CON
15
Concentra Group Holdings Parent, Inc.
CON
$3.05B
| $34.7M | 1.23% | 1,600,000 -1,900,000 | -54% | -$41.2M |
|
16
Evolent Health
EVH
$1.12B
| $28.4M | 1.01% | 3,000,000 -1,000,000 | -25% | -$9.47M |
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $21.9M | 0.78% | 725,000 +100,000 | +16% | +$3.02M |
|
18
Myriad Genetics
MYGN
$593M
| $20.8M | 0.74% | 2,350,000 -750,000 | -24% | -$6.65M |
|
19
ZimVie
ZIMV
$532M
| $20.4M | 0.72% | 1,885,000 -840,000 | -31% | -$9.07M |
|
20
MoonLake Immunotherapeutics
MLTX
$3.54B
| $17.2M | 0.61% | 441,000 | – | – |
|
21
Denali Therapeutics
DNLI
$2.23B
| $17M | 0.6% | 1,250,000 -1,000,000 | -44% | -$13.6M |
|
22
AnaptysBio
ANAB
$569M
| $13.9M | 0.5% | 750,000 -500,000 | -40% | -$9.3M |
|
23
Theravance Biopharma
TBPH
$699M
| $8.93M | 0.32% | 1,000,000 | – | – |
|
24
10x Genomics
TXG
$1.74B
| $8.73M | 0.31% | 1,000,000 | – | – |
|
25
Inogen
INGN
$216M
| $6.95M | 0.25% | 975,000 -1,025,000 | -51% | -$7.31M |
|